Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2020
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I MutationIgnacio Perez-Valero, Josep M Llibre, Antonella Castagna, et al.
The Lancet. Infectious Diseases|June 9, 2014
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trialAnton Pozniak, Martin Markowitz, Anthony Mills, et al.
HIV Clinical Trials|July 11, 2017
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTIAnton Pozniak, Jason Flamm, Andrea Antinori, et al.
Infection & Chemotherapy|October 6, 2016
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical TrialsJun Yong Choi, Somnuek Sungkanuparph, Thanomsak Anekthananon, et al.
AIDS (London, England)|February 10, 2018
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trialsKirsten White, Will Garner, Lilian Wei, et al.
HIV Medicine|May 9, 2022
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of ageFranco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, et al.
Infectious Diseases and Therapy|March 9, 2021
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label TrialFranco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, et al.
HIV Research & Clinical Practice|July 16, 2019
Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trialsYeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, et al.
AIDS (London, England)|December 20, 2015
Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b studyJan van Lunzen, Andrea Antinori, Calvin J Cohen, et al.
Plos One|January 30, 2020
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimensGregory D Huhn, Moti Ramgopal, Mamta K Jain, et al.
Pageof 3